Raising Capital to Complete the Clean Room Unit of Rahpouyan Fanavar Sadegh — Third Stage

  Rahpouyan Fanavar Sadegh began operations in 1397, drawing on its specialists in biochemistry, chemical engineering, genetics, and biological sciences and collaborating with various academic centers, with the aim of producing polysaccharide vaccines, including Hib, pneumococcal, and meningitis vaccines, as well as other vaccines needed in the country, such as IPV, rotavirus, and pentavalent vaccines. The company's objectives were established with regard to meeting domestic demand for these vaccines and the importance of establishing vaccine production lines within the country. These vaccines will be added to the national vaccination program in the coming years. The company's plans have been designed and implemented on a 5120-square-meter site in Pardis Science and Technology Park, across four floors comprising laboratories, production units, and offices. Currently, approximately three years after the company began its substantive operations, 80 percent progress has been achieved, as confirmed by the Ministry of Industry and Mines. Rahpouyan Fanavar Sadegh has assembled a specialist team of individuals with experience in vaccine and pharmaceutical production in the country. Relying on the transfer of domestic knowledge from academia to industry and working with international consultants, it has placed the completion of production technology for these vaccines on its agenda. Alongside research and development on the production of the target vaccines, the company has successfully obtained microbial strains that produce active pharmaceutical ingredients and is optimizing production methods and developing the final formulations of these vaccines. The total capital requested by the applicant is 150,000 million rials, to be raised in four stages through the Halal Fund platform. In the third stage, the applicant will receive financing of 36،000 million rials. Given its field of activity, Rahpouyan Fanavar Sadegh has designed and built a clean room complex covering 500 square meters. This section includes various units, including small-scale product sample production, R&D, and product quality control. Equipping and commissioning the clean room requires infrastructure and technical work. To date, the chiller and air handling unit, panel installation, lighting and electrical system, and its BMS system have been fully completed in this unit. Based on the work carried out so far, it is estimated that 90 percent of the clean room complex has been completed. The aim of this section of Rahpouyan Fanavar Sadegh is to provide technology and technical know-how packages and QC services to customers and companies engaged in biotechnology pharmaceutical products that seek to develop technical know-how domestically and abroad. It has already negotiated with several pharmaceutical companies and is on the verge of signing contracts. According to the estimates, the cost of establishing and commissioning the clean room complex amounts to 1,100 billion rials. Investment to date has been 800 billion rials, and completing this unit requires financing of 300 billion (fixed and working capital). Private partners will provide 150 billion of the required capital. To finance the remaining costs, the company is requesting crowdfunding of 150 billion rials through the Halal Fund platform, to be carried out in 4 stages. With the injection of funds, the company will be able to use the prepared space to provide services. Based on the estimates, monthly revenue of 2,000 million rials is possible during the first few months of operation. In subsequent months, with project completion and marketing, monthly revenue of 25,000 million rials is possible through the sale of technical packages and the provision of other services. Accordingly, a share of revenue has been envisaged for investors participating in this project. Taking into account the investors' 15 percent share of revenue, their return on investment in this project is estimated at 25 percent. The project is backed by a guarantee issued by the New Technologies Development Fund under Sepas number 2411001024808095, valid until 03/05/1402 and renewable at the request of Hesab Yari Amin Melal Company. This project  uses a flexible funding model and will be considered successful upon raising at least half of the amount  requested by the applicant. The composition of the Board of Directors is as follows: 1. Seyyed Ehsan Ranai Siadat: Chairman of the Board 2. Seyyed Omid Ranai Siadat: Vice Chairman of the Board 3. Seyyed Taha Ranai Siadat: Board Member 4. Hassan Koochakzadeh: CEO and Board Member Shareholders holding more than 10 percent are as follows: Seyyed Taha Ranai Siadat and Seyyed Ehsan Ranai Siadat The draft participation agreement between the investor and the applicant, along with the applicant's business plan, is accessible through the links below.http://hlfd.ir/rfs1http://hlfd.ir/rfs2 First Quarterly Report Second Quarterly Report Unaudited 6-Month Report   Project Symbol: Halafanavar/ Halalfnr
Project symbol: حلافناور/halalfnr